期刊文献+

痛泻要方对溃疡性结肠炎模型大鼠血清IL-12含量及NPY水平影响的研究 被引量:4

Effects of Tongxieyaofang on serum levels of interleukin- 12 and neuropeptide Y in rats with ulcerative colitis
原文传递
导出
摘要 目的:探讨痛泻要方对溃疡性结肠炎(UC)模型大鼠IL-12及神经肽(NPY)的影响。方法:将SD大鼠随机分为空白组、模型组、柳氮磺嘧啶(SASP)组及痛泻要方高、中、低剂量组,每组各10只;采用TNBS/乙醇溶液灌肠法制备溃疡性结肠炎大鼠模型,运用ELISA法测定各组血清中细胞因子IL-12、神经肽Y(NPY)的含量。结果:与空白组比较,模型组血清IL-12、NPY水平均显著上升(P<0.01),各治疗组较模型组血清IL-12、NPY水平均明显下降(P<0.01)。结论:痛泻要方能通过下调IL-12、NPY的表达,调节肠道异常免疫反应,维持Th1、Th2的平衡,抑制炎症反应,修复溃疡,进而防治UC。 Objective: To investigate the effects of Tongxieyaofang on the serum levels of interleukin- 12( IL-12) and neuropeptide Y( NPY) in rats with ulcerative colitis( UC). Methods: Sprague- Dawley rats were randomly divided into blank group,model group,salicylazosulfapyridine( SASP) group,and high-,medium-,and low- dose Xongxieyaofang groups,with 10 rats in each group. TNBS / alcohol solution was given to establish the rat model of UC,and ELISA was used to measure the serum levels of IL- 12 and NPY in each group. Results: Compared with the blank group,the model group had significant increases in the serum levels of IL- 12 and NPY( P〈0. 01). After treatment,all treated groups had significant reductions in the serum levels of IL- 12 and NPY compared with the model group( P〈0. 01). Conclusion: Tongxieyaofang can reduce the serum levels of IL- 12 and NPY,regulate abnormal intestinal immune response,maintain the balance between Th1 and Th2 cells,inhibit inflammatory response,repair ulcers,and thus prevent and treatment UC.
机构地区 湖南中医药大学
出处 《湖南中医杂志》 2016年第4期166-167,共2页 Hunan Journal of Traditional Chinese Medicine
关键词 溃疡性结肠炎 大鼠 痛泻要方 IL-12 NPY 实验研究 ulcerative colitis rat Tongxieyaofang interleukin-12 neuropeptide Y experimental study
  • 相关文献

参考文献5

二级参考文献158

  • 1Narender N, Ratna P, Shailendra G,et al . T-bet is essential for the progression of experimental autoimmune encephalomyelitis [J] . Immunology,2006,118 (3) :384-391.
  • 2Guo C,Chu X,Shi Y,et al . Correction of Thl-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura [J] . J Clin Immunol,2007,27 (6):557-562.
  • 3Stasi R,Del Poeta G,Stipa E,et al . Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura [J] . Blood, 2007,110(8):2924-2930.
  • 4Reefer AJ,Satinover SM,Solga MD,et al . Analysis of CD25hiCD4^+ "regulatory" T-cell subtypes in atopic dermatitis reveals a novel T (H)2-like population [J] . J Allergy Clin Immunol,2008,121(2): 415-422.
  • 5Koenders MI,joosten LA,van den Berg WB . Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to turnout necrosis factor and IL-I in experimental arthritis [J] . Ann Rheum Dis, 2006, 65: 29-33.
  • 6Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197.
  • 7Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147:258-267.
  • 8Armstrong AM, Gardiner KR, Kirk SJ, Halliday MI, Rowlands BJ. Tumour necrosis factor and inflammatory bowel disease. Br J Surg 1997; 84:1051-1058.
  • 9Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8:171-178.
  • 10Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 2005; 206:296-305.

共引文献61

同被引文献80

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部